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ABSTRACT 
 
 Objective: To examine the efficacy of an unguided, self-help CBT booklet on 
hot flush and night sweat (HFNS) problem rating, delivered in a work setting. 
 Methods: Women aged 45-60 years, having 10 or more problematic HFNS a 
week, were recruited to a multicentre randomised controlled trial, via the occupational 
health/human resources departments of eight organisations. Participants were 1:1 
randomised to Self-Help CBT (SH-CBT) or No Treatment Waitlist Control (NTWC). 
The primary outcome was HFNS problem rating; secondary outcomes included 
HFNS frequency, work and social adjustment, sleep, mood, beliefs and behaviours, 
and work-related variables (absence, performance, turnover intention and work 
impairment due to presenteeism). Intention-to-treat analysis was used, and between-
group differences estimated using linear mixed models. 
 Results: 124 women were randomly allocated to SH-CBT (n=60) and NTWC 
(n=64). 104 (84%) were assessed for primary outcome at 6 weeks and 102 (82%) at 
20 weeks. SH-CBT significantly reduced HFNS problem rating at 6 weeks (SH-CBT 
versus NTWC adjusted mean difference, -1.49; 95% CI, -2.11 - -0.86; p < 0.001) and 
at 20 weeks (-1.09 95% CI, -1.87 - -0.31; p < 0.01). SH-CBT also significantly 
reduced HFNS frequency at 6 weeks; improved work and social adjustment, sleep, 
menopause beliefs, HFNS beliefs/behaviours at 6 and 20 weeks; and reduced work 
impairment due to menopause-related presenteeism at 20 weeks, compared to the 
NTWC. There was no difference between groups in other work-related outcomes.  
 Conclusions: A brief, unguided self-help CBT booklet is a potentially 
effective management option for working women experiencing problematic HFNS. 
 
Keywords: Menopause; Work; Menopausal symptoms; Hot flushes; Cognitive 
behaviour therapy; Vasomotor symptoms; RCT 
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What we already know 
 
Menopausal symptoms - hot flushes and night sweats (HFNS) - are particularly 
difficult for women to deal with at work, due to embarrassment, discomfort and some 
aspects of the work environment. Cognitive behaviour therapy (CBT) for HFNS is an 
effective non-medical intervention that can help women to manage these symptoms. 
CBT is effective when delivered in groups or as a self-help booklet, but CBT is not 
generally available to employees in the workplace. 
 
 
What this study adds 
 
This study demonstrates that an unguided self-help CBT approach can be effective in 
reducing the impact and frequency of HFNS experienced by working women. In 
addition, work and social functioning and sleep problems improved to a greater extent 
for those receiving SH-CBT compared to NTWC, and there were benefits to 
wellbeing and reports of somatic symptoms at 20 weeks. While there was no 
difference between the groups in work related outcomes (absence, performance, 
turnover intention), there was an improvement in the SH-CBT group’s perceived 
work ability in spite of menopause-related difficulties (presenteeism) compared to 
NTWC. 
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INTRODUCTION 
 
With rising employment rates for women and an ageing profile of the workforce 
in the UK and most European countries, increasing numbers of women will be 
working during their menopause transition and postmenopause.1,2 As a result 
there is growing interest in improving the health and wellbeing of working 
women, and retaining and increasing the numbers of experienced older women 
in the workplace. Recent recommendations and guidance also stress the 
importance of improving the experience of menopause for working women.3-5 
There are over 3.5 million women in employment aged between 50 and 65 in the UK6 
and, given that menopause (final menstruation) occurs on average between the ages of 
50–51 and the menopause transition can last for up to ten years,7 a significant 
proportion of female workers will be experiencing menopausal symptoms. While 
many women go through the menopause with few problems, approximately 20-30% 
have troublesome symptoms that impact on their quality of life.8,9 Hot flushes and 
night sweats (HFNS) are the main menopausal symptoms and these are particularly 
difficult to manage in work contexts, due to physical discomfort, social 
embarrassment and the effects of disturbed sleep.10 As well as hot flushes, women 
have been found to report that tiredness, memory/concentration, and loss of 
confidence are problematic at work.11  
Women are generally reluctant to disclose their menopausal status, particularly at 
work, where embarrassment and fear of ridicule is common, and self-control is highly 
valued. Hot flushes may draw attention to menopausal status, particularly during 
formal meetings, when working with men and/or younger adults or in hot 
environments.10,12-13 Discussion about the menopause at work is widely perceived as 
taboo14 and consequently, despite women’s reported experiences, there is a lack of 
awareness about menopause in work settings.  
Although an under-researched area, several cross-sectional studies have examined the 
impact of work environment on experience of menopause, as well as the impact of 
menopause upon work performance. There is some evidence that menopausal 
symptoms can have an effect on work experience, e.g. perceived performance, and 
that certain work situations and physical working environments, such as aspects of 
work design and temperature, and work stress, can increase the intensity of 
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menopausal symptoms.11,15-21 However, Jack and colleagues in a recent systematic 
review22 concluded that while some working women who had bothersome 
menopausal symptoms reported impaired work outcomes, the overall evidence 
was inconclusive. Moreover, surveys of work-related stress in the UK23 suggest that 
women aged 45-54 report more work-related stress than mid-aged men or women of 
any other age group. There are likely to be complex relationships between work-
related stress and the experience of menopausal symptoms.24    
Griffiths and colleagues11 conducted a study of 896 women employed in ten UK-
based organisations. Women suggested several areas requiring organisational change 
in order to improve women’s experience of menopause at work; these included: (i) 
greater awareness among managers about menopause as a possible occupational 
health issue, (ii) flexible working hours, (iii) access to information and sources of 
support at work, and (iv) attention to work place temperature and ventilation. The 
current study aims to address (iii) as outlined in the study protocol paper.25 
Hormone therapy (HT) is an effective medical treatment for menopausal symptoms26 
but not all women want to take it due to contraindications and personal preference. 
Cognitive behaviour therapy (CBT) is recommended for anxiety and depression 
during the menopause26 and a CBT intervention has been developed to help women to 
manage HFNS,27-30 that is based on a theoretical model31 supported by recent 
empirical studies.32-34 HFNS can be potentiated by stress and are exacerbated by 
negative beliefs and behavioural reactions. The intervention therefore includes 
psychoeducation and evidence-based CBT strategies to reduce stress, and to manage 
hot flushes, night sweats and sleep. CBT for HFNS has been found to be effective in 
reducing the impact of HFNS, i.e. how problematic they are, in several clinical 
trials,27-29 frequency of night sweats27 and physiologically monitored HFNS.35 CBT 
was recommended as an effective treatment for vasomotor symptoms in a recent 
position statement on non-hormonal interventions, by the North American Menopause 
Society.36  
Group CBT and self-help CBT (a self-help booklet containing the same information 
with a breathing/relaxation CD) formats for HFNS have been shown to be equally 
effective in reducing the impact of HFNS;27 however, group CBT had more impact on 
mood and quality of life. Self-help CBT has also been found to produce similar levels 
of improvement when delivered with minimal guidance.30 Although CBT 
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interventions for HFNS are available in self-help and group formats,37-38 there have 
not been any previous work based trials and CBT interventions for HFNS are not yet 
widely accessible to women at work.  
We hypothesised that CBT will be more effective than no treatment in: (i) 
reducing the impact of HFNS (problem-rating),11 and (ii) reducing HFNS frequency, 
moderating menopause beliefs, HFNS beliefs and behaviours, improving mood, 
sleep, work and social adjustment, and work outcomes (work absence, presenteeism, 
job performance, and turnover intention).   
 
 
 
METHODS 
 
 The trial is reported in accordance with the CONSORT guidelines for 
randomised controlled trials39 and is described in detail in a trial protocol 
paper25 (trial registration: ClinicalTrials.gov identifier: NCT02623374). 
Ethical approval was obtained from Kings College London Research Ethics 
Committee (Psychiatry, Nursing and Midwifery Research Ethics Subcommittee, 
reference: RESCMR-14/15-0475).  
 
Participants and procedure 
Eight organisations, from public and private sectors, participated in the study. 
Organisations volunteered to take part in response to talks given at conferences or 
other occupational health-related events, and by direct contact. Each participating 
organisation had a ‘gatekeeper’ who was responsible for disseminating recruitment 
materials (posters, leaflets, emails) within the organisation. The research team also 
gave presentations within organisations to raise awareness of the project and invite 
eligible women, who self-referred, to take part.  
 Participants were menopausal women with problematic HFNS. Inclusion 
criteria were: women, employed within participating organisations, English speaking, 
aged 45-60 years, having problematic HFNS for at least 2 months (scoring above 2 on 
the Hot Flush Rating Scale7, minimum frequency of 10 a week), and having no 
      7 
current major physical or mental health problems that would compromise 
participation. 
 Potential participants contacted the trial coordinator by telephone or email and 
were provided with a verbal description of the study, and if interested to proceed, 
were screened by telephone. Those eligible were sent a participant information sheet, 
consent form and a baseline questionnaire, with a self-addressed and stamped 
envelope to return the signed and dated consent form, and questionnaire. Data were 
collected at Kings College London and participating organisations. Participants who 
returned signed consent and baseline questionnaires were randomly allocated into one 
of two arms: treatment or control (figure 1). Randomisation was performed using 
Microsoft Excel with a ratio of 1:1, stratifying by recruiting centre. Participants 
allocated to the treatment group were posted the self-help booklet. Data entry was 
performed by a researcher blind to group allocation and statistical analysis by the trial 
statistician who was also blind to treatment condition. 
 Participants were asked to completed follow-up questionnaires at 6 weeks and 
20 weeks post-randomisation. A prize draw of £50 Amazon voucher (or similar) was 
offered as an incentive to complete all three questionnaires. The participants in the 
Self-help CBT arm were also invited to take part in an evaluation interview via 
telephone after returning the final follow-up questionnaire.  
   
Intervention 
 The Self-Help CBT booklet (SH-CBT) was adapted from the self-help booklet 
used in the MENOS2 trial27,37 (see protocol paper25). The booklet was adapted and 
shortened, with additional sections covering work stress and how to discuss 
menopause at work. Pilot work was conducted to assess the acceptability, content and 
format of the intervention and questionnaires, as well as the delivery method. We also 
explored potential barriers and difficulties for women using the SH-CBT intervention. 
Telephone interviews were conducted with working menopausal women (n=10) who 
had been sent the booklet from four of the participating organisations. Women noted 
that having the word menopause on the front cover might cause embarrassment and 
reduce use of the booklet. The preferred delivery of the self-help intervention and 
questionnaires was in paper form, although several mentioned that an online option 
might be preferred, by some women. Feedback was addressed; modifications included 
adding content about how to have conversations with line managers at work, an 
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infographic that can be given to a line manager when attempting to have the 
discussion, removal of the word menopause from the front page, and adding examples 
from work situations throughout the booklet. The final revised booklet and 
questionnaires were also reviewed by an advisory group (comprising working 
menopausal women, academic researchers, trade union representatives, employers) 
and minor amendments/corrections made.   
 The final SH-CBT intervention was an A5 sized, colour booklet with 
instructions and four chapters (with information, exercises and homework tasks) to be 
completed over four weeks. Chapters covered psycho-education about menopause and 
HFNS, stress management, breathing/relaxation, and learning cognitive and 
behavioural strategies to help manage HFNS, stress and sleep, with individual goal 
setting and weekly homework. A relaxation and breathing exercise was also provided 
on a CD, which was included with the booklet, together with an infographic.  
 Participants in the no treatment waitlist control (NTWC) condition did not 
receive SH-CBT during the treatment phase but were sent the SH-CBT booklet after 
the 20 week assessment, off-trial. All participants were able to access their general 
practitioner and other health care options.  
 
Measures 
 Demographic information (age, ethnicity, height, weight, education, 
relationship and 
employment status), smoking, alcohol intake and exercise behaviour, menopausal 
status (menopause transition/postmenopause), treatment experience, and work 
variables (type of job, working hours, shift working, age and gender of work 
colleagues) were recorded at baseline. All data was self-reported.  
 
Primary outcome 
 The primary outcome was HFNS Problem Rating10 at 6 weeks and 20 weeks 
post randomisation. Problem rating was measured by a subscale of the Hot Flush 
Rating Scale as used in the MENOS2 trial,27 containing three items: “To what extent 
do you regard your flushes/sweats as a problem?”; “How distressed do you feel about 
your hot flushes?” and “How much do your hot flushes interfere with your daily 
routine?” Items are measured on a 10 point scale ranging from 1 to 10, with high 
scores indicating more problematic hot flushes; a two point change on this scale is 
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generally considered clinically significant.27-28 Cronbach alpha (α) for this measure 
was 0.83 at baseline. 
 
Secondary outcomes 
HF Frequency: HFNS frequency was measured with the Hot Flush Rating Scale7, 
which records of the number of HFNS experienced in the previous week.  
 HFNS Beliefs and Behaviours: A shortened version of the Hot Flush Belief 
Scale40 and the Hot Flush Behaviour Scale41 were used (see supplementary file in 
Protocol paper25). Beliefs were measured using a mean score of 10 items, producing 
three sub-scales: beliefs about HF in a social context (at baseline, α=0.89); 
coping/control over HF (α=0.73); and beliefs about NS and sleep (α=0.60). 
Behaviours were measured from a mean score of 6 items producing two sub-scales: 
avoidance behaviour (at baseline, α=0.80) and positive behaviours (α=0.48). 
Responses ranged from 0 (strongly disagree) to 5 (strongly agree).   
 The Menopause Representations Questionnaire (MRQ)42 was used to assess 
women’s cognitive representations of the menopause with respect to identity 
(attribution of symptoms to menopause), consequences, and control/cure. The MRQ 
comprising of 37 items, using a 5 point Likert scale ranging from strongly agree (5) to 
strongly disagree (1). Mean scores on the subscales are calculated. Cronbach alpha for 
the subscales at baseline were: identity .80, negative impact .74, new phase .67, relief 
.47, control/cure .77. 
 The Revised Women’s Health Questionnaire (WHQ)43 was used to measure 
perceptions of physical and emotional health. The revised WHQ has 23 items and has 
been found to have the same if not improved psychometric properties than the original 
in a recent study in a recent study.44 The following subscales examined in this study: 
anxiety/depression, wellbeing, somatic symptoms sleep problems, and 
memory/concentration (baseline α=0.62, 0.66, 0.68, 0.62, 0.72, respectively).  
A single item measure of sleep quality was added from the Pittsburgh Sleep Quality 
Index (PSQI),45 which is a self-rated questionnaire assessing sleep quality over a 1-
month time interval using a 4-point Likert scale (1= “Very bad” to 4 = “Very good”). 
The Work and Social Adjustment Scale (WSAS) 46 is a five-item scale used to 
measure functional impairment at home, work and in social situations attributed to a 
specific problem (menopausal symptoms). Items are measured from 0 (no 
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impairment) to 8 (very severely impaired) and summed to produce a final score out of 
40 (α=0.88). 
 
Work related outcomes: 
Absenteeism is the total number of days affected by work absence in the last 4 weeks 
attributed to the menopause. The number of days off work due to symptoms, the 
number of days arrived to work late, and the number of days left work early due to 
their menopause were summed to create this variable.  
Job performance was measured using a single item 5-point Likert scale, 1 (poor) to 5 
(excellent) where participants were asked to rate their perceived performance in 
relation to others. 
The Stanford Presenteeism Scale47 was used to measure menopausal women’s 
perceptions of being physically present at their jobs, but experiencing decreased 
productivity and below-normal work quality due to their menopause. Using 6-items, 
the average scores on a five point Likert-type scale, ranging from strongly disagree 
(1) to strongly agree (5) were calculated (α=0.79). Higher scores suggest low 
perceived work impairment due to the menopause. 
Turnover intention was measured using an existing 4-item measure48, with 5-point 
Likert scales, to assess the employee’s intention to leave the organisation (α=0.81). A 
higher score suggests a greater intention to leave the organisation.  
  Any medical, non-medical and over the counter treatments used and health 
services accessed for menopause during the treatment phase (post randomization) 
were logged at the 20 week follow-up. 
Analysis of additional variables: attitude to menopause at work, disclosure, job 
stress and job satisfaction, resilience, intention to reduce working hours or stop 
working because of the menopause, will be reported elsewhere, together with a 
mediation analysis. 
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Sample size  
Based on previous studies,27-28 a total sample size of 80 participants, 40 per arm, are 
required to detect 2 points difference in HFNS mean score at 6 weeks using regression 
analysis controlling for baseline level of the outcome, with a 90% power at 2 tailed 
significance 0.05 level, assuming equal SD (3.0) for both groups and correlation 
between baseline and follow up measures at 0.4 for the purpose of being conservative. 
After taking into account 20% loss to follow up rate, a total sample size of 100 is 
required, 50 per arm.  
 
Statistical analysis 
Group comparisons were carried out using the (modified) intention-to-treat principle, 
with participants providing data on at least one post-randomisation assessment 
analysed in the group to which they were randomised. Treatment effects for the 
primary (HFNS problem rating) and secondary outcomes were estimated using linear 
mixed models. The post-randomisation values of the outcome variables at 6 and 20 
weeks were included as the outcome. Indicator variables for time, group, and a time 
by group interaction term and a recruiting centre indicator variables were included as 
covariates to allow treatment effects to vary by group at the two post-randomisation 
assessments. A random intercept for each participant was included to account for the 
repeated assessment of the outcome variable. Adjusted mean differences are presented 
unstandardised (i.e. original scale units) and as a standardised mean differences (i.e. 
standard deviation units; SMD) where the adjusted mean difference is divided by the 
pooled standard deviation of the outcome at baseline. 
Prior to estimating the treatment effects, the suitability of the variables for 
analysis was considered by inspecting their distributions by group at each time points. 
Residual diagnostics were performed for the mixed effects models to confirm the 
assumption that outcome variables follow an approximately normal distribution was 
not violated.    
The maximum likelihood estimator employed produces unbiased and efficient 
estimates of the treatment effect when missing outcome data arises at random 
conditional on the covariates included (i.e. missing at random). Sensitivity analyses 
were performed by comparing the treatment effect estimates to those where missing 
outcome assessments were imputed using the last observed value of the outcome (i.e. 
last observation carried forward). In addition, for the primary outcome, additional 
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sensitivity analysis was performed using a pattern-mixture model approach to 
determine the impact of a range of reasonable missing data scenarios on the treatment 
effect estimate.49 
The recorded evaluation interviews were transcribed and a thematic content analysis 
was performed using the software NVivo (version21). Categories were developed 
under four main themes, including the impact of the intervention, reasons for the 
impact and for no impact experienced, perceptions of the intervention’s content and 
delivery, and suggestions for improvement.  
 
RESULTS 
Participants 
124 participants were randomised from eight, public (n=6) and private sector (n=2), 
organisations in the UK. Of these, 106 (85.5%) completed at least one post-
randomisation assessment and were included in the (modified) intention-to-treat 
analysis. Overall attrition was below 20%, but it was higher in the SH-CBT group 
compared to the NTWC group with 60 (93.8%) and 46 (76.7%) included in the 
analysis, respectively. Participant flow through the trial is shown in figure 1. 
Table 1 presents demographic information at baseline. Women were, on average, 54 
years old and 70% were of white ethnicity. The sample was fairly healthy, with the 
majority rating their general health as good to excellent (85%). Over two-thirds were 
non-smokers and were drinking less than 7 units of alcohol per week. Most women 
exercised at least twice a week (68%). Women generally did not have a current 
mental or physical health problem (85%), nor were receiving treatment for breast 
cancer (95%). They had experienced their last menstrual period (LMP) on average 4 
years before entering the study. Four per cent (n=5) were taking hormone therapy 
(HT), and 18% (n=20) were prior HT users; 32.5% (n=40) were taking over the 
counter remedies or medication for the menopause and 23% (n=29) had sought 
medical help for menopause in the past 6 months.   
Just over three-quarters (83%) of women worked full-time, with regular hours, not 
shift work. The majority worked in non-manual jobs (82%), with both male and 
female colleagues (65%) having a mixed age range (73%). At baseline, the number of 
days affected by absence (including whole days, arriving to work late, leaving work 
early), that women attributed to menopause averaged 2 days (mean=1.80, sd=4.22) at 
baseline, over the past 4 weeks. Half (50.8%, n=63) had disclosed that they were 
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going through the menopause to a line manager, but only 9.7% (n=12) disclosed that 
menopause was a reason for any work absence. The majority rated their work 
performance as very good or excellent (79.9%, n=91).  
[INSERT TABLE 1 AND FIG 1 HERE] 
 
Outcomes   
At baseline women reported having an average of 56.24 (range 0-245) HFNS per 
week, and these were rated as problematic (mean 6.5/10); the average duration of 
HFNS was 35 (SD=32.6) months (range 2 to 192 months). 
 
Primary outcome 
Unadjusted and baseline adjusted mean differences are shown in Table 2. The 
adjusted mean difference in the primary outcome HFNS Problem-rating, controlling 
for baseline level, was -1.49 (p<0.001) in favour of the SH-CBT group at 6 weeks, 
and -1.09 (p <0.01) at 20 weeks. These differences translate to a moderate to large 
effect sizes of d=-0.77 and -0.56, respectively (Table 2 and Fig 2).  
No selection bias due to differential attrition by baseline problem rating was apparent. 
There was only a small difference in HFNS Problem-rating mean baseline scores in 
the NTWC group between those completing (N=60) and not completing (N=4) at 
post-randomisation assessment, and therefore included in the analysis: 6.80 versus 
7.33. Similarly, there was only a small difference in baseline scores in the SH-CBT 
group between those completing (N=46) and not completing (N=14) at post-
randomisation assessment: 6.25 versus 6.10. Those who did not complete were 
significantly more likely to be of non-white ethnicity (Pearson chi square=4.38, p 
<0.05), not in a relationship, chi-squ=5.61, p <0.05) and to score higher on HFNS 
avoidance behaviour (Mean rank=85.89) to those included (Mean rank=58.53), U = 
1375, z = -3.056, p <0.01, and not receiving treatment for any major physical or 
health problem (Chi square=6.63, p <0.01). There were no significant differences in 
HFNS frequency or problem rating.  
Sensitivity analysis was conducted to determine the impact of missing data at post-
randomisation assessments on the estimated treatment effect size at 6-weeks. The last 
observation carried forward approach including all randomised participants indicated 
a more conservative effect size of 0.51. A pattern-mixture model approach was 
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employed to examine the sensitivity of the treatment effect as a result of the higher 
attrition in the SH-CBT group. This suggested that those with missing data in the 
intervention group would have had to experience worsening of 3 points on average 
relative to their baseline values to reduce the treatment effect to non-significant. Such 
a difference appears implausible.  
 [INSERT TABLE 2 and FIG 2 HERE] 
 
Secondary outcomes 
 In addition to the significant moderate to large effect on the primary outcome 
there was a significant effect on HFNS frequency at the 6 week and the 20 week 
assessment, effect sizes 0.39 and 0.31 respectively. HFNS frequency was highly 
variable; total HFNS frequency reduced on average by 24% SH-CBT, 0.5% NTWC at 
6 weeks, and by 35.5% SH-CBT and 15% for NTC at 26 weeks.  
There was a significant effect of SH-CBT on levels of functioning measured by the 
Work and Social Adjustment Scale (WSAS)46 at both 6 and 20 week assessments. 
There were significant group differences in WHQ wellbeing and somatic symptom 
scores at 20 weeks, and in sleep problems at 6 and 20 weeks. Similarly, significant 
improvements in sleep quality were recorded at 6 and 20 weeks as assessed by the 
Pittsburg Sleep Quality Index.45 (see Table 2 and Fig 2). 
 Large and moderate significant effects were observed for the beliefs about 
menopause and beliefs/behaviours about HFNS. SH-CBT participants viewed 
menopause as more controllable and curable and as a new phase (MRQ control/cure 
and new phase subscales) significantly more than NTWC at both 6 and 20 week 
assessments. Effects on other MRQ subscales were small and generally non-
significant. Moderate to large significant effects were observed for the three HFNS 
beliefs scales and for the positive behaviours subscale. The effect on avoidant 
behaviours was small and non-significant. 
In relation to work variables, effects were generally small and non-significant for 
absence (days affected by any absence in past 4 weeks and attributed to menopause 
including whole days, arriving to work late, leaving work early), performance, and 
turnover intention. However, for presenteeism (Stanford Presenteeism Scale47) at 20 
weeks, the effect of SH-CBT compared to NTWC was significant and approaching a 
large effect size. Those receiving SH-CBT had higher scores at 20 weeks than the 
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NTWC group, indicating lower perceived work impairment due to the menopause for 
the SH-CBT group. 
 
Use of services and medication 
 Since starting the study (randomisation to 20 week assessment), 14% 
(n=6) of the SH-CBT and 15% (n=9) of the NTWC participants had sought 
medical help, on average once, for menopause symptoms - a nonsignificant 
difference. One woman (SH-CBT group) was prescribed antidepressants for 
anxiety/mood swings; in the NTWC group, two were prescribed HT, one the 
contraceptive pill and two changed type of hormone therapy. Eight (NTWC=7, 
SH-CBT=1) had used non-medical or herbal treatments since starting the study: 
homeopathy (n=1 NTWC), evening primrose oil (n=3 NTWC), red clover (n=1 
NTWC), sage tablets (n=1 NTWC) and Menopace, one participant from each 
group). 
 
Adherence and acceptability  
 At the 6 week follow-up assessment, 61% (n=27) of SH-CBT participants 
had read the entire self-help booklet, and an additional 21% (n=9) more than 
half. The majority (82%, n=32) had used the relaxation/breathing exercise at 
least 1-2 times a week or more, at the onset of a hot flush (82%, n=37) and to 
help manage a stressful situation at work (71%, n=25). Similarly, at 20 weeks, 
65% (n=28) of SH-CBT participants had read all of the self-help booklet, and 
26% (n=11) more than half. Relaxation/breathing was reportedly still being 
used by 79% (n=33) at least 1-2 times a week or more. 
 At 6 weeks 89.4% (n=42) rated the self-help booklet as being helpful in 
coping with their menopause symptoms at work; 23.4% (n=11) moderately and 
31.9% (n=15) very/extremely helpful. At the 20 week assessment 88.1% (n=35) 
rated the self-help booklet as helpful in coping with their menopause symptoms 
at work; 26.2% (n=11) moderately and 45.2% (n=19) very/extremely helpful.  
 
Evaluation interviews 
 Twenty-seven women were interviewed at the end of the trial from the 
intervention group. We originally intended to select 50% of transcripts for 
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analysis,22 but as only 27 women took part in interviews, all their data were 
included. The majority, 82%, felt that the intervention had impacted positively 
on their experience of HFNS, 48% mentioning a reduction specifically in HFNS 
frequency. Positive benefits were reported to life in general (63%), and to 
working life (52%). Since the start of the trial, 37% had talked about their 
menopause to their line manager.  
 Reasons given for improvements in general to life included: changing 
perceptions about the menopause and having a better understanding, exercising 
self-care, and having the confidence to talk and to be open about their 
menopause. Positive changes to working life were attributed to addressing HFNS 
triggers identified during the SH-CBT, feeling less bothered or focused on 
symptoms, using the breathing techniques and letting go, and also having more 
confidence at work. Participants who did not experience any impact from the 
intervention stated it was because they were already doing things to help 
manage symptoms anyway they did not follow the self-help or their HFNS had 
improved.  
  In terms of the self-help booklet content, the main aspects that the 
participants mentioned as being helpful, were that it was informative, 
particularly the materials on managing HFNS, e.g. addressing thoughts, the CBT 
approach, and identifying triggers; they also liked the dairies and interactive 
elements of the booklet (e.g. exercises to complete). Other helpful aspects 
included having testimonials and perceptions of others presented in the booklet, 
the breathing exercise and CD, the goal setting section, as well as the general 
design and structure of the booklet. Approximately two thirds liked the hard-
copy format of the booklet; however, some thought that having an online version 
or an app for smart phones could be offered in the future. 
 
DISCUSSION 
 
The aim of this multicentre study was to investigate the impact of a brief, 
unguided, self-help CBT intervention on HFNS, for women having problematic 
menopausal symptoms in the work context. When compared to a no -treatment 
control group, unguided self-help CBT significantly reduced HFNS problem 
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rating with moderate to large effect sizes and improvements were maintained at 
20 weeks post-randomisation. These results are consistent with findings from 
previous randomised controlled trials of CBT for HFNS, when delivered in-group 
and guided self-help booklet formats. 27-30 However, it is noteworthy that this study 
implemented a considerably briefer version of SH-CBT with no additional support, 
and in a work, rather than a clinical context.  
 HFNS frequency also reduced at both time points and group differences 
were significant at both 6 weeks and 20 weeks. Percentage reduction in 
frequency of 24% (6 weeks) and 35.5% (20 weeks) was broadly similar to that 
found in previous studies of guided self-help; 27,30 relatively small changes were 
evident for the NTWC group. In the MENOS 2 trial27 HFNS frequency assessed by 
sternal skin conductance monitoring also significantly improved following CBT, 
suggesting that changes might occur at both subjective and physiological levels.35  
The significant improvements on the Work and Social Adjustment Scale (WSAS) 
scores at both 6 weeks and 20 weeks post-randomisation compared to the 
control group, provide evidence of the secondary benefits of SH-CBT to 
functioning at work, home, leisure, and in social situations. The WSAS is routinely 
used in primary care psychology services in the UK and has been found to reflect a 
distinct social functioning factor and to be sensitive to treatment effects.50 There were 
significant group differences in wellbeing and somatic symptoms at 20, but not at 6, 
weeks; but not anxiety/depression nor memory/concentration subscales of the Revised 
WHQ.  However, WHQ sleep problems subscales scores and sleep quality 
significantly improved following SH-CBT at 6 and 20 weeks. The CBT intervention 
includes advice and strategies to improve sleep and CBT is an effective treatment for 
insomnia.51  
CBT for HFNS targets cognitions (catastrophic or shameful thoughts in social 
contexts, worries about the consequences of night-time wakening), overly negative 
beliefs about menopause, behavioural reactions, and stress/well-being. Mediation 
analyses of previous trials have shown that CBT appears to work by changing 
symptom perceptions and cognitive appraisals (women’s perceptions, attitudes and 
beliefs about menopause and symptoms) and well as using helpful behavioural 
strategies.33-34 Consistent with this work, we found significant changes in beliefs and 
behaviours about HFNS following SH-CBT, suggesting that the treatment is 
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targeting relevant cognitions and behaviours. More general beliefs about th e 
menopause, reflected in MRQ subscales negative impact, control/cure and new 
phase subscales, also showed significant between group differences at both 6 and 
20 week assessments.  
The current findings therefore lend support to the cognitive model of HFNS.31 The 
social aspects of these beliefs – relating to social meanings about the menopause and 
concern about other people’s views when having hot flushes - are relevant because 
women report embarrassment and fear of ridicule particularly in work contexts.10,12,13 
More positive/neutral beliefs about menopause, e.g. that symptoms are controllable 
and that menopause can herald a new life phase, are associated with more positive and 
helpful beliefs about HFNS, e.g. that others may not think negatively about them, that 
women have strategies to cope with them; and, in turn, positive and neutral beliefs 
about HFNS are associated with less problematic HFNS.32,40-41 
The majority of women (80%) rated their work performance as very good or 
excellent at baseline. Presenteeism, using the Stanford Presenteeism Scale,45 
measures menopausal women’s perceptions of productivity and work impairment due 
to their menopause while being physically present at work. Higher scores suggest low 
perceived work impairment due to the menopause; i.e. women are at work and 
managing any work impairment so that their performance is not affected. The SH-
CBT group obtained significantly higher scores than NTC at 20 weeks. It is possible 
therefore that the strategies learnt from the SH-CBT might enable women to manage 
their HFNS so that they have less impact on their work. HFNS become less 
problematic and social and work functioning improves. The relationships between 
improvements in HFNS and presenteeism will be explored in a future publication.  
The lack of impact on additional work outcomes may relate to the timeframes 
used in the trial. It is possible that 20 weeks post-randomization, or 
approximately 16 weeks post treatment, was insufficient time for changes in 
work adjustment to occur. For example, the significant between group difference 
in presenteeism was only found at 20 weeks and not at 6 weeks.  
Alternatively, problematic HFNS may not impact on all work outcomes in similar 
ways. The workplace is a complex environment; the experience of HFNS may 
interact with several employee related and work-related factors. A review by 
Jack and colleagues22 identified that the work environment, both physical and 
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psychosocial, may influence women’s experience of menopause. Further analysis 
of the potential moderating effect of a number of work related factors (work 
environment, job satisfaction and job stress) is planned. 
 Overall, our results suggest that an unguided, self-help CBT approach may 
be efficacious as a low intensive treatment option for working women with 
problematic menopause symptoms. The levels of frequency and problem-rating 
HFNS at baseline were very similar to the levels of well women and breast cancer 
patients recruited into clinical trials,27-29 and the improvements following this low-
intensity version of SH-CBT were robust and sustained. Comparable recommended 
non-hormonal treatments for HFNS involve several sessions of treatment, e.g. 5-12 
sessions of hypnosis and 8 sessions of mindfulness:36 while hormonal and non-
hormonal medical treatments involve appointments and ongoing prescription 
charges. The intervention involves no health professional time and is likely therefore 
to be cost effective; however, a health economic analysis is recommended. The 
intervention appeared to be acceptable in terms of feedback reported during 
interviews, and the women’s reports on what was helpful were consistent with 
qualitative data collected during the MENOS2 trial.52 
 
Strengths and limitations 
 The trial was adequately powered, there were no adverse events, 
relatively low levels of attrition during the trial period, and adherence to the SH-
CBT was reasonable. The SH-CBT was piloted and modified in response to 
feedback. Unexpectedly, dropouts were higher in the SH-CBT than the NTWC 
condition, which is a limitation. Most women in the SH-CBT arm who dropped 
out reported time pressures as the main problem for not completing the self -
help intervention and questionnaires. It is possible that the women in the NTWC 
arm may have been more likely to persist in the study because they were 
expecting to obtain the SH-CBT off trial at the end of the study. Participants who 
dropped out were more likely to be non-white, not in a relationship, to have 
higher baseline HFNS avoidance behaviour scores, and not having any current 
treatment for any major physical or mental health problem. In previous trials, 
ethnicity either did not moderate the effects of CBT,34 or when it did it was 
women of non-white ethnicity who were more likely to benefit from CBT.33 It is 
      20 
possible that the self-help booklet was less appealing or acceptable to some 
women, who may have had less support, and, for others, being avoidant about 
HFNS could reflect a more general strategy (i.e. avoiding the self-help book 
designed to help manage HFNS). Pilot work was conducted to assess the 
acceptability, content and format of the intervention and questionnaires, as well as 
the delivery method, and adjustments made, but we did not actively target women 
from a range of ethnic groups. Further exploration is needed into the 
acceptability of the booklet, its format, and the level of individual or group 
support in different organisations, in order to increase adherence to the 
intervention.   
 Assessment of work outcomes relied on subjective rather than 
objective measures.  However, obtaining formal sickness absence data and 
standard measurements of job performance for different job roles in 
heterogeneous workplaces is a complex matter and was beyond the scope of this 
study. Further, this might have been perceived, by participants, as compromising 
the anonymous nature of their responses. 
 
Implications and future research 
 The trial findings have implications for various key stakeholders; 
employers, occupational health professionals, trade union representatives, and 
other professionals with a role in workplace health and wellbeing, may wish to 
make self-help CBT available to staff who have bothersome menopause 
symptoms. Similarly, policy makers should ensure that sufficient awareness and 
provision of information and help is offered to staff who may be experiencing 
menopause-related difficulties at work, in line with recent recommendations.1,3-
5,53 
Several suggestions for future research have been mentioned above. The 
format and level of detail of the provision of information for working women 
could be considered in future research; for example, whether briefer 
information is made available for all staff, with SH-CBT offered to those who 
have problematic symptoms. The needs and working environments of 
organisations are likely to vary. SH-CBT is available in book format 37 and 
workshops or groups could be offered using the manual for health 
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professionals.38 It may also be of interest to explore the effect of self-help for 
other symptoms reported by women at work (e.g. confidence, fatigue) in more 
detail, and to clarify the extent to which these are affected by, or interact with 
for example work stress and HFNS. Recommendations for improving the 
experience of menopause at work include changes at an individual level and at 
an organisational level.3-5 Similarly, we would predict that the SH-CBT 
intervention for women with troublesome menopausal symptoms might be 
more effective when offered in the context of a broader strategy to improve 
awareness about menopause in general, to reduce stigma and to make 
appropriate changes to work environment.53  
 
CONCLUSIONS 
To our knowledge this is the first study to develop and evaluate an unguided, 
self-help intervention specifically to help menopausal women to manage HFNS in 
the workplace. The results suggest that SH-CBT is an effective and acceptable 
low-intensity, non-medical intervention for problematic HFNS that has 
additional effects on work and social adjustment and on presenteeism. The study 
is timely, and has important implications for employers and other stakeholders 
who have a responsibility to provide resources for working women.  
 
 
 
"This is a non-final version of an article published in 
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Table 1.  Baseline demographics, health, and job status of participants 
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Participant 
demographics  
SH-CBT 
(N=60) 
NTWC 
(N=64) 
Total  
(N=124) 
Age  Mean (SD) 54.04 (3.17) 54.10 (3.53) 54.09 (3.4) 
 
Ethnicity 
 
White British 
 
42 (70.0% 
 
45 (71.4%) 
 
87 (70.7%) 
 Black British  11 (18.3%)  14 (22.2%) 25 (18.3%) 
 Other 7 (11.7%) 4 (6.4%) 11 (8.9%) 
 
Menopausal 
status 
 
 
 
 
 
 
 
Menopause transition 
Postmenopause 
 
11 (20%) 
44 (80%) 
 
20 (35.7%) 
36 (64.3%) 
 
 
31 (27.9%) 
80 (72.1%) 
Last menstrual period 
(months) Mean (SD) 
48.29 (54.16) 35.68 (51.69) 42.04 (53.09) 
Hysterectomy 10 (17.0%) 6 (10.0%) 17 (14.0%) 
Oophorectomy 3 (5.0%) 6 (10.0%) 9 (7.0%) 
    
Relationship 
status  
  
 
 
Education  
 
 
 
Employment 
Single 11 (18.3%) 15 (25%) 27 (21.8%) 
Married/Partnered 42 (70.0%) 37 (57.8%) 79 (63.8%) 
Divorced/Separated/ 
Widowed 
 
7 (11.7%) 11 (17.2%) 18 (14.5%) 
Left school at 16  16 (26.7%) 17 (28.3%) 34 (28.1%) 
Left school at 18 7 (11.7%) 4 (6.7%) 11 (9.1%) 
Degree 37 (61.6%) 39 (65%) 76 (62.8%) 
 
Full-time 
 
46 (76.7%) 
 
56 (89.1%) 
 
103 (83.0%) 
 
 
Smoking  
Part-time 14 (23.3%) 7 (10.9%) 21 (17.0%) 
 
Non smoker 
 
38 (64.4%) 
 
26 (40.6%) 
 
64 (52.0%) 
 
 
 
Exercise 
Past smoker 14 (23.7%) 26 (40.6%) 40 (32.5%) 
Current Smoker 7 (11.9%) 12 (18.8%) 19 (15.4%) 
 
Rarely/Never 
 
4 (6.8%) 
 
6 (9.4%) 
 
10 (8.1%) 
 
 
 
 
 
Alcohol   
Once a week or less 13 (22.1%) 16 (25.0%) 29 (23.4%) 
2-3 times a week 26 (44.1%) 24 (37.5%) 50 (40.7%) 
4-6 times a week 9 (15.3%) 11 (17.2%) 20 (16.3%) 
Every day 7 (11.9%) 7 (10.9%) 14 (11.4%) 
 
None 
 
21 (35.6%) 
 
22 (34.4%) 
 
43 (35.0%) 
 
 
 
BMI 
1-13 Units 31 (52.5%) 37 (57.8%) 68 (55.3%) 
14+ Units 7 (11.9%) 5 (7.8%) 12 (9.8%) 
 
Mean (SD) 
 
25.66 (4.91) 
 
28.26 (4.12 
 
27.04 (4.67) 
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Table 2. Unadjusted and adjusted group differences for primary and secondary 
outcomes  
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 28 
  SH-CBT NTWControl                      Adjusted mean difference 
 Time N 
 
Mean  
 
SD 
 
N 
Mean SD 
Differ
ence SE 
p-
value 
Lowe
r 
95%C
I 
Uppe
r 
95%C
I 
Effect 
size 
HF/NS 
Problem 
Rating Baseline 46 6.25 1.97 60 6.80 1.90       
 6 weeks 44 4.38 2.21 60 6.16 2.31 -1.49 0.32 0.001 -2.11 -0.86 0.77 
 20 weeks 42 4.36 2.29 59 5.80 2.30 -1.09 0.40 0.01 -1.87 -0.31 0.56 
HF/NS 
Frequency Baseline 46 53.13 34.34 60 54.28 38.11       
 6 weeks 44 40.59 26.05 59 54.02 43.00 
-
14.01 5.05 0.01 
-
23.91 -4.10 0.39 
 20 weeks 43 34.28 27.62 59 46.03 37.92 
-
11.36 5.26 0.05 
-
21.66 -1.05 0.31 
WSAS Baseline 46 12.74 9.77 60 12.67 8.44       
 6 weeks 44 8.52 8.24 59 10.90 8.09 -2.36 0.83 0.01 -3.98 -0.74 0.26 
 20 weeks 43 8.65 8.65 57 11.81 8.39 -2.89 0.98 0.01 -4.80 -0.98 0.32 
Sleep Quality Baseline 44 1.82 0.81 60 1.85 0.82       
 6 weeks 44 1.30 0.67 58 1.69 0.78 -0.41 0.11 0.001 -0.63 -0.20 0.51 
 20 weeks 42 1.40 0.77 58 1.66 0.78 -0.24 0.10 0.05 -0.44 -0.03 0.29 
WHQ 
anxiety/depre
ssion Baseline 45 67.53 22.12 60 63.01 19.97       
 6 weeks 44 70.90 22.30 60 64.12 22.31 2.88 2.59 ns -2.20 7.96 0.14 
 20 weeks 42 74.85 23.97 58 66.10 21.42 4.81 2.78 ns -0.64 10.26 0.23 
WHQ 
wellbeing Baseline 45 71.11 15.65 60 66.94 19.47       
 6 weeks 44 71.40 19.72 60 67.92 19.58 1.70 2.55 ns -3.31 6.71 0.09 
 20 weeks 42 75.79 16.44 57 67.54 17.30 6.62 2.40 0.01 1.91 11.33 0.37 
WHQ somatic 
symptoms Baseline 45 50.37 23.93 60 47.67 21.43       
 6 weeks 44 53.48 24.42 60 49.22 22.74 2.71 3.11 ns -3.39 8.80 0.12 
 20 weeks 42 58.41 22.47 57 49.94 20.04 8.38 2.80 0.01 2.90 13.86 0.37 
WHQ memory 
& 
concentration Baseline 45 45.92 28.09 60 41.31 24.39       
 6 weeks 44 48.47 26.91 60 42.41 24.24 3.07 3.19 ns -3.18 9.33 0.12 
 20 weeks 42 51.33 25.97 57 44.25 23.15 4.58 3.03 ns -1.36 10.52 0.18 
WHQ sleep 
problems Baseline 44 34.09 25.66 60 37.78 26.01       
 6 weeks 44 46.97 27.91 60 37.22 26.10 12.75 3.22 0.001 6.45 19.06 0.49 
 20 weeks 42 48.41 21.72 56 40.77 30.47 12.39 3.79 0.001 4.96 19.82 0.48 
MRQ negative 
impact Baseline 46 2.17 0.73 60 2.27 0.83       
 6 weeks 43 2.13 0.91 60 2.45 0.77 -0.23 0.11 0.05 -0.45 -0.01 0.29 
 20 weeks 43 2.09 0.84 59 2.38 0.69 -0.21 0.10 0.05 -0.41 -0.01 0.27 
MRQ relief Baseline 46 2.52 0.82 60 2.37 0.96       
 6 weeks 43 2.64 0.95 60 2.50 0.95 0.03 0.13 ns -0.22 0.29 0.04 
 20 weeks 43 2.70 0.84 59 2.37 1.00 0.25 0.11 0.024 0.03 0.46 0.28 
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MRQ new 
phase Baseline 46 1.72 0.92 60 1.73 0.87       
 6 weeks 43 2.13 0.77 60 1.71 0.91 0.41 0.12 0.001 0.17 0.65 0.46 
 20 weeks 43 2.22 0.74 59 1.89 0.76 0.29 0.11 0.01 0.08 0.51 0.33 
MRQ 
control/cure Baseline 46 2.11 0.63 60 1.94 0.90       
 6 weeks 43 2.82 0.81 60 2.05 0.84 0.64 0.11 0.001 0.43 0.86 0.81 
 20 weeks 43 2.88 0.65 59 2.10 0.80 0.66 0.11 0.001 0.44 0.88 0.83 
MRQ identity Baseline 46 17.17 8.28 60 15.80 8.00       
 6 weeks 43 16.35 9.08 60 15.28 7.98 -0.22 1.07 ns -2.31 1.87 0.03 
 20 weeks 43 16.40 7.52 59 15.97 8.61 -0.41 1.08 ns -2.53 1.71 0.05 
HF social 
beliefs Baseline 46 2.35 1.67 60 2.30 1.37       
 6 weeks 44 1.59 1.35 60 2.40 1.38 -0.80 0.15 0.001 -1.09 -0.51 0.53 
 20 weeks 42 1.55 1.27 57 2.24 1.39 -0.64 0.14 0.001 -0.91 -0.37 0.43 
HF 
coping/contro
l beliefs Baseline 46 2.26 1.22 60 2.45 1.06       
 6 weeks 44 1.57 1.14 60 2.31 1.17 -0.60 0.16 0.001 -0.91 -0.29 0.53 
 20 weeks 42 1.77 1.23 58 2.29 1.20 -0.47 0.18 0.01 -0.83 -0.11 0.42 
NS/sleep 
beliefs Baseline 46 2.08 1.09 60 2.42 1.33       
 6 weeks 44 1.29 1.09 60 2.36 1.41 -0.90 0.16 0.001 -1.21 -0.58 0.73 
 20 weeks 42 1.26 0.90 57 2.08 1.31 -0.64 0.16 0.001 -0.95 -0.33 0.52 
HF/NS 
avoidant 
behaviours Baseline 46 0.75 1.03 60 1.19 1.41       
 6 weeks 44 0.65 1.00 60 1.21 1.28 -0.25 0.15 0.05 -0.54 0.04 0.20 
 20 weeks 42 0.79 1.03 57 1.25 1.51 -0.16 0.20 ns -0.55 0.23 0.13 
HF/NS 
positive 
behaviours Baseline 46 3.34 1.01 60 3.13 1.19       
 6 weeks 44 3.67 0.86 60 3.11 1.13 0.43 0.14 0.01 0.15 0.71 0.39 
 20 weeks 42 3.64 1.07 58 3.13 1.17 0.41 0.18 0.05 0.06 0.75 0.37 
Absenteeism 
(days), 4 
weeks Baseline 46 1.17 3.93 60 2.20 4.25       
 6 weeks 46 0.50 2.25 60 1.13 2.16 -0.54 0.44 ns -1.40 0.32 0.13 
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 20 weeks 46 0.70 3.00 60 1.43 3.27 -0.64 0.55 ns -1.71 0.43 0.16 
SPS 
Presenteeism Baseline 46 20.24 6.34 60 18.67 6.40       
 6 weeks 43 22.12 7.16 59 19.36 6.93 1.64 0.90 ns -0.13 3.41 0.26 
 20 weeks 43 23.21 5.84 57 18.18 7.18 4.18 0.80 0.001 2.60 5.76 0.65 
Turnover 
intention Baseline 46 2.43 0.97 60 2.67 0.96       
 6 weeks 43 2.32 1.02 59 2.67 0.90 -0.20 0.12 ns -0.43 0.03 -0.21 
 20 weeks 42 2.48 1.06 58 2.50 0.93 0.09 0.12 ns 0.14 0.31 0.09 
Job 
performance Baseline 46 4.07 0.83 59 4.07 0.93       
 6 weeks 44 4.20 0.76 60 4.18 0.83 -0.02 0.12 ns -0.25 0.22 -0.02 
 20 weeks 43 4.30 0.71 59 4.10 0.74 0.16 0.12 ns -0.07 0.40 0.19 
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Figure 1. Flow chart of trial 
 
Figure 2. Standard mean differences between SH-CBT vs NTWC groups in HFNS 
problem rating and frequency, interference (WSAS), sleep quality, 
menopause appraisals and HFNS beliefs and behaviours. Positive values 
favour intervention. 
 
Figure 3. Standard mean differences between SH-CBT vs NTWC groups in work 
related variables. Positive values favour intervention. 
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   Screened for Eligibility (n=172)   
 
 
Enrolment 
     Excluded (n=27) 
Problematic HF/NS <2months,  
<10 per week (n=21) 
Did not want to participate (n=2) 
Age <45 years (n=4) 
  Consent Baseline assessment 
(n=145) 
Information sheet and consent 
form and baseline questionnaires. 
  Excluded (n=21)   
Lack of consent 
 
 
      
  Randomised (n=124) 
Baseline questionnaire received. 
Randomization, stratified by 
organisation 1:1 
  
       
Allocation: 
Participants 
Organisations 
 SH-CBT (n=60) 
Organisation 1 (n=7) 
 Organisation 2 (n=19) 
 Organisation 3 (n=10) 
Organisation 4 (n=8) 
Organisation 5 (n=3) 
Organisation 6 (n=2) 
Organisation 7 (n=4) 
Organisation 8 (n=7) 
 NTWC (n=64) 
Organisation 1 (n=13) 
Organisation 2 (n=19) 
Organisation 3 (n=7) 
Organisation 4 (n=7) 
Organisation 5 (n=2) 
Organisation 6 (n=6) 
Organisation 7 (n=4) 
Organisation 8 (n=6) 
  
 
 
       
  Group sample (n=44) 
Lost to follow-up (n=16): 
Unable to contact (n=2) 
Qu not returned (n=5) 
Time constraints (n=4) 
Ill health/personal (n=4)  
No more symptoms (n=1)  
 Group sample (n=60) 
Lost to follow-up (n=4): 
Sought other treatment (n=1) 
Not contactable (n=1) 
Qu not returned (n=1) 
Time constraints (n=1) 
  
 
6 
week follow-
up (n=104) 
Lost to follow-
up (n=20) 
  
       
  Group sample (n=43) 
Lost to follow-up (n=3): 
Completed Qu at 20 but 
not 6 weeks (n=2) 
Qu not returned (n=2) 
Feeling overwhelmed (n=1) 
 Group sample (n=59) 
Lost to follow-up (n=1): 
Time constraints (n=1) 
  
20 week 
follow-up 
(n=102) 
Lost to follow-
up (n=2) 
Analysed  
(n=106) 
 Total analysed  (n=46) 
Excluded (n=14) 
 Total analysed  (n=60) 
Excluded (n=4) 
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HFNS Problem Rating
HFNS frequency
WSAS
Sleep quality
MRQ negative impact
MRQ relief
MRQ new phase
MRQ control cure
HF beliefs in social context
HF beliefs coping/control
Beliefs about NS/sleep
Avoidance behaviours
Positive coping behaviours
-.5 -.2 0 .2 .5 .8 1.2
                                         Standardised mean difference
6 weeks
20 weeks
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